Houston, TX — December 17th, 2025 — OmniScience, the company behind Vivo, the first agentic AI control tower for clinical trials, has been named a top three innovator in DayOne’s 2025 HealthTech x Pharma R&D Innovation Showcase, following a highly competitive selection process that evaluated more than 200 companies across 40 countries.

Earlier this year, OmniScience was selected as one of just 10 companies worldwide invited to join the DayOne accelerator cohort. Applicants spanned drug discovery, biomarkers, competitive intelligence, data management, and clinical operations technologies. After months of rigorous evaluation, collaboration, and live pitching, OmniScience was ultimately recognized as a top three company by a panel of expert judges representing global investors and leading pharmaceutical organizations including Johnson & Johnson, Roche, CSL, Novartis, Novo Nordisk, and Debiopharm.

DayOne is a globally recognized health innovation accelerator that connects high-potential startups with leading pharmaceutical organizations to advance the future of pharma R&D. The HealthTech x Pharma R&D Accelerator focuses on solutions addressing critical challenges across clinical development, data management, and operational efficiency.

OmniScience’s platform, Vivo, serves as a cognitive partner for clinical teams unifying fragmented clinical and operational data, delivering explainable, real-time insights, and proactively identifying risk across studies and portfolios. Designed by clinical data science experts, Vivo enables sponsors to move from reactive oversight to proactive, intelligent decision-making.

“Being selected as a top three innovator by a panel of industry-leading judges is a powerful validation of both our technology and our team,” said Angela Holmes, CEO of OmniScience. “Out of hundreds of global pharma R&D innovators, advancing to the final ten—and ultimately being named top three—reflects the growing demand for agentic AI systems that can meaningfully improve how clinical trials are run.”

The accelerator culminated in a live pitch event at the Roche campus in Basel, where OmniScience presented alongside fellow finalists to an audience of pharma executives, investors, and innovation leaders.

This recognition builds on OmniScience’s continued momentum, including selection into Johnson & Johnson’s JLABS, recognition as a Vendor to Watch in the IDC MarketScape report on AI in clinical trials, and strategic partnerships expanding Vivo’s real-world impact.